一品红芩香清解口服液获批国家中药保护品种

Core Viewpoint - The approval of Qinxiangqing Oral Liquid as a national secondary protected variety of traditional Chinese medicine is expected to enhance the company's intellectual property protection and market competitiveness in the pediatric medicine sector, positively impacting its operations [1] Group 1 - The State Drug Administration has approved Yipin Hong's wholly-owned subsidiary, Yipin Hong Biopharmaceutical Co., Ltd., for the Qinxiangqing Oral Liquid [1] - The approval is classified as a national secondary protected variety of traditional Chinese medicine [1] - This development is anticipated to strengthen the company's product intellectual property protection [1] Group 2 - The approval is expected to enhance the market competitiveness of the product in the children's medicine field [1] - The positive impact on the company's production and operations is highlighted [1]